Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ZK 219477 as first-line therapy in extensive-stage small cell lung cancer
2005-000597-53Phase 2Completed
- Sponsor
- Schering AG
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sagopilone in small cell lung cancer (SCLC), sponsored by Schering AG. Primary endpoint: Objective response rate (CR + PR). Started Oct 2005; status: completed.
02
Drugs
sagopilone
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2005-000597-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000597-53.